ChemoCentryx, Inc.
(NASDAQ GS: CCXI)
Rigrodsky Law, P.A. is investigating ChemoCentryx, Inc. (“ChemoCentryx”) regarding possible breaches of fiduciary duties and other violations of law related to ChemoCentryx’s agreement to be acquired by Amgen. Under the terms of the agreement, ChemoCentryx’s shareholders will receive $52.00 per share.